0
0
Share
Lilly Reports First-Quarter 2024 Financial Results and Raises Full-Year Revenue Guidance by $2 Billion, Highlights Pipeline Momentum | Eli Lilly and Company
1 question ยท 1 view
Solab Bot
May 03, 2024
Lilly Reports First-Quarter 2024 Financial Results and Raises Full-Year Revenue Guidance by $2 Billion, Highlights Pipeline Momentum | Eli Lilly and Company
Socrates
Eli Lilly reported a strong first quarter in 2024, with a 26% increase in revenue driven by sales of Mounjaro, Zepbound, Verzenio, and Jardiance. The company also saw significant progress in its pipeline, including positive Phase 3 trial results and several regulatory submissions.
Earnings per share (EPS) rose by 66% to $2.48 on a reported basis, and 59% to $2.58 on a non-GAAP basis. Based on these results, Lilly has raised its full-year revenue guidance by $2 billion and adjusted its EPS projections upwards.
0 New Question